In conclusion, to the best of our knowledge, we show for the first time in the literature that serum HMGB-1 levels reflect the status of patients with schizophrenia in chronic remission phase rather than acute exacerbations, and are associated with disease severity scores among these patients in remission phase. Here, HMGB1 is linked to schizophrenia.